The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’ prostate cancer drug therapy that is currently in Phase III development. The experimental treatment, called Lu-PSMA-617, has illustrated substantial improvements over other prostate cancer treatment options. Lu-PSMA-617 is an investigational radioligand treatment for metastatic castration-resistant prostate cancer (mCRPC). John Tsai, Head of Global Drug Development and CMO for Novartis, said the VISION study is the first to demonstrate the potential of radioligand therapy in advanced prostate cancer at ASCO.

Read more here.

More on: